Clinical Guidance: Approaches to Treatment-Resistant Depression in Adolescents

Clinical Guidance: Approaches to Treatment-Resistant Depression in Adolescents | Research Domain Criteria | Clinical Guidance: Maintenance Treatment of the Bipolar II Patient Who Responds to an Antidepressant | Clinical Guidance: Treatment of Obsessive-Compulsive Symptoms in Schizophrenia

Adolescents who had not responded to an initial trial of antidepressant treatment improved when cognitive-behavioral therapy or a mood stabilizer was added to their treatment during the first 12 weeks. Emslie et al. (p. 782) report that these treatments added after 12 weeks did not alter outcome. Venlafaxine was no more effective than a serotonin reuptake inhibitor as a second-line drug, although there was a nonsignificant trend for it to be helpful later in the course of treatment. Adolescents who had remissions were already showing improvement at 6 weeks. More vigorous intervention is recommended for those who are not continuing to improve between 6 and 12 weeks (figure, above). John Walkup points out in an editorial (p. 734) that the pace of pharmacological intervention was more rapid than in general clinical practice, which may account for the relatively good outcome, with 39% of patients remitted by 24 weeks.

View Large | Download Slide(.ppt)
Add to My POL

Figure 1.

Research Domain Criteria

The National Institute of Mental Health (NIMH) has initiated research to determine how genetic and neurobiological abnormalities could be used to identify different pathophysiological types of mental disorders. NIMH Director Thomas Insel and colleagues (p. 748) envision a matrix of domains, ranging from molecular to psychosocial, that can specify treatments and outcomes more accurately than phenomenological diagnosis alone can do.

Clinical Guidance: Maintenance Treatment of the Bipolar II Patient Who Responds to an Antidepressant

Although depression is the major burden of bipolar disorder for many patients, most studies show that antidepressants do not improve outcome for either depression or mania in bipolar patients. However, a subgroup of bipolar II patients does respond to antidepressants. Amsterdam and Shults (p. 792) report that this subgroup continues to have less recurrence of depression when they are treated with fluoxetine than if they are switched to lithium or placebo (figure, below). In an editorial (p. 738), Trisha Suppes points out that even in this subgroup, selected for a prior response to fluoxetine, maintenance treatment with fluoxetine results in more mood instability than occurs with lithium or placebo. Nonetheless, they appear to have an overall positive course with antidepressant treatment.

View Large | Download Slide(.ppt)
Add to My POL

Figure 2.

Clinical Guidance: Treatment of Obsessive-Compulsive Symptoms in Schizophrenia

Rodriguez et al. (CME, p. 754) report the case of a patient with marked obsessional symptoms during his first episode of schizophrenia. These symptoms did not respond to treatment with typical or atypical antipsychotics combined with selective serotonin reuptake inhibitors or clomipramine. A brief trial of exposure and response prevention therapy seemed helpful, and the combination of clozapine and lamotrigine led to substantial improvement. Targeting of obsessive-compulsive symptoms with these therapeutic modalities may be indicated for patients whose obsessive-compulsive symptoms are more marked than is consistent with their other psychotic symptoms or persist after treatment of the psychosis.

Download all saved figures as a .zip file.

View Large
Download Slide(.ppt)

Add to My POL

Figure 1.

View Large
Download Slide(.ppt)

Add to My POL

Figure 2.

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.

Submit a Comments

Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of JBJS editorial staff.

* = Required Field

Comment Author(s)*(if multiple authors, separate names by comma)

Example: John Doe

Affiliation & Institution*

Comment Title*

Comment*

Cancel

Print
PDF
E-mail

Recipient(s) will receive an email with a link (good for 72 hours) to 'In This Issue' and do not need to have American Journal of Psychiatry account to access the content.
Your Name:*
Example: John Doe

Email Address:* CC Me:
Enter your valid email address. Example: jdoe@example.com

Recipient's Email Address:*
Separate multiple email address with semi-colons (up to 5).

Subject:* 's American Journal of Psychiatry: 'In This Issue'
Subject for your email.

Message:
(Optional, message will truncate at 1000 characters)

Processing your request... Please Wait...

Copyright © in the material you requested is held by The American Psychiatric Association (unless otherwise noted). This email ability is provided as a courtesy, and by using it you agree that you are requesting the material solely for personal, non-commercial use, and that it is subject to The American Psychiatric Association's Terms of Use. The information provided in order to email this topic will not be used to send unsolicited email, nor will it be furnished to third parties. Please refer to The American Psychiatric Association's Privacy Policy for further information.

Copyright © American Psychiatric Association. All rights reserved.
Share
Get Citation

In This Issue. American Journal of Psychiatry. 2010 Jul;167(7):A14-A14.

Download citation file:

RIS (Zotero)

EndNote

BibTex

Medlars

ProCite

RefWorks

Reference Manager

Copyright © American Psychiatric Association. All rights reserved.
Reprints
Data Supplements

Supporting Data
July 2010 Residents' Journal